UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

British journal of clinical pharmacology, 2013-12, Vol.76 (6), p.908-916

2013

Volltextzugriff (PDF)

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.637-645

2016

Volltextzugriff (PDF)

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban

British journal of clinical pharmacology, 2014-10, Vol.78 (4), p.877-885

2014

Volltextzugriff (PDF)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical pharmacology: advances and applications, 2014-01, Vol.6 (default), p.179-187

2014

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects

International journal of clinical pharmacology and therapeutics, 2014-07, Vol.52 (7), p.564

2014

Volltextzugriff (PDF)

LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column

Bioanalysis, 2014-08, Vol.6 (15), p.2071-2082

2014

Volltextzugriff (PDF)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Clinical pharmacology: advances and applications, 2013-01, Vol.5 (Issue 1), p.59-66

2013

Volltextzugriff (PDF)

Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003-10, Vol.795 (2), p.215-226

2003

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.628-636

2016

Volltextzugriff (PDF)

A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006-02, Vol.831 (1), p.213-222

2006

Volltextzugriff (PDF)

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

Thrombosis and haemostasis, 2012-05, Vol.107 (5), p.916-924

2012

Volltextzugriff (PDF)

Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma

Journal of pharmaceutical and biomedical analysis, 2015-03, Vol.107, p.409-418

2015

Volltextzugriff (PDF)

Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

Blood, 2014-12, Vol.124 (21), p.345-345

2014

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients

Clinical drug investigation, 2014-02, Vol.34 (2), p.117-126

2014

Volltextzugriff (PDF)

Response to Letter to the Editor From Drs. Stöllberger and Finsterer: Original Publication: “Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban”

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.648-649

2016

Volltextzugriff (PDF)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

Clinical pharmacology: advances and applications, 2018-01, Vol.10, p.153-163

2018

Volltextzugriff (PDF)

Response to Letter to the Editor From Drs. Stöllberger and Finsterer

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.648-649

2016

Volltextzugriff (PDF)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

Clinical pharmacology: advances and applications, 2018-01, Vol.10, p.153

2018

Volltextzugriff (PDF)

Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors

Drug metabolism and disposition, 2010-11, Vol.38 (11), p.1962-1966

2010

Volltextzugriff (PDF)

Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology

Drug metabolism and disposition, 2012-12, Vol.40 (12), p.2374-2380

2012

Volltextzugriff (PDF)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]

Clinical pharmacology: advances and applications, 2018-01, Vol.10, p.71-72

2018

Volltextzugriff (PDF)

Disposition of radiolabeled BMS-204352 in rats and dogs

Biopharmaceutics & drug disposition, 2002-01, Vol.23 (1), p.41-46

2002

Volltextzugriff (PDF)

Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans

Drug metabolism and disposition, 2011-05, Vol.39 (5), p.891-903

2011

Volltextzugriff (PDF)

Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin

Cancer research (Chicago, Ill.), 1995-07, Vol.55 (14), p.3060-3067

1995

Volltextzugriff (PDF)

Liquid–liquid extraction of strongly protein bound BMS-299897 from human plasma and cerebrospinal fluid, followed by high-performance liquid chromatography/tandem mass spectrometry

Journal of pharmaceutical and biomedical analysis, 2007-04, Vol.43 (5), p.1728-1736

2007

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects

LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma

Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients

Response to Letter to the Editor From Drs. Stöllberger and Finsterer: Original Publication: “Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban”

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

Response to Letter to the Editor From Drs. Stöllberger and Finsterer

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors

Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]

Disposition of radiolabeled BMS-204352 in rats and dogs

Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans

Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin

Liquid–liquid extraction of strongly protein bound BMS-299897 from human plasma and cerebrospinal fluid, followed by high-performance liquid chromatography/tandem mass spectrometry

Suchergebnisse filtern